NCT07075237View on ClinicalTrials.gov

Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

March 31, 2027

Conditions
Schizophrenia
Interventions
DRUG

Paliperidone Palmitate Injection (PP1M)

"Day 0: 150 mg deltoid injection; Day 7: 100 mg deltoid injection; Monthly maintenance dose of 75-150 mg (deltoid or gluteal) for 6 months (dose adjusted per investigator's judgment).~To avoid missed doses, administration is permitted ±7 days around the scheduled monthly date."

Trial Locations (1)

210024

Nanjing Brain Hospital, Nanjing

All Listed Sponsors
lead

Jiangsu Province Nanjing Brain Hospital

OTHER